ES2156902T3 - Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes. - Google Patents
Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes.Info
- Publication number
- ES2156902T3 ES2156902T3 ES94927602T ES94927602T ES2156902T3 ES 2156902 T3 ES2156902 T3 ES 2156902T3 ES 94927602 T ES94927602 T ES 94927602T ES 94927602 T ES94927602 T ES 94927602T ES 2156902 T3 ES2156902 T3 ES 2156902T3
- Authority
- ES
- Spain
- Prior art keywords
- sequences
- peptides
- hiv
- nucleotides
- vintages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 2
- 230000003248 secreting effect Effects 0.000 abstract 2
- 101150048348 GP41 gene Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE DESCRIBEN PEPTIDOS QUE EDUCEN ANTICUERPOS, QUE INCLUYEN PREFERIBLEMENTE ANTICUERPOS SECRETORES SEGREGADOS POR SUPERFICIES MUCOSALES, QUE MUESTRAN ACTIVIDAD NEUTRALIZANTE CONTRA DIFERENTES CEPAS Y AISLADOS CLINICOS DEL VIH-1 Y QUE INHIBEN LA FUSION DE LAS CELULAS PROVOCADA POR EL VIH-1, LOS PEPTIDOS ESTAN COMPUESTOS DE UNA SECUENCIA DE 7 U 8 AMINOACIDOS QUE SE CORRESPONDEN CON AQUELLOS EN GP41 DE GP160 DEL BH10 AISLADO DEL VIH EN LA POSICION 662 A 668 (ELDKWAS) O EN LA POSICION 661 A 668 (LELDKWAS) RESPECTIVAMENTE, QUE INCLUYEN PREFERIBLEMENTE LOS PEPTIDOS QUE ESTAN COMPUESTOS DE LA SECUENCIA ELDNWAS, ELNKWAS, LELDNWAS O LELMKWAS O QUE ESTAN GENETICAMENTE CODIFICADOS POR SECUENCIAS DE NUCLEOTIDOS QUE SE CORRESPONDEN CON LAS SECUENCIAS DE AMINOACIDOS, O POR SECUENCIAS QUE SE HIBRIDAN CON LAS SECUENCIAS DE NUCLEOTIDOS, O POR SECUENCIAS DEDUCIDAS A PARTIR DE LAS SECUENCIAS DE NUCLEOTIDOS POR DEGENERACION. PREFERIBLEMENTE LOS PEPTIDOS SUSTITUYEN UNA O MAS PARTES DE LA SECUENCIA DE AMINOACIDODE LA PROTEINA VIRAL O SE INSERTAN EN ZONAS ANTIGENICAS DE UNA PROTEINA VIRAL, POR EJEMPLO, MEDIANTE FUSION DE SECUENCIAS DE NUCLEOTIDOS RESPECTIVAS, Y LA EXPRESION SUBSECUENTE DE LOS GENES DE FUSION SE LLEVA A CABO EN UN SISTEMA DE EXPRESION BIOLOGICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93114631 | 1993-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2156902T3 true ES2156902T3 (es) | 2001-08-01 |
Family
ID=8213253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94927602T Expired - Lifetime ES2156902T3 (es) | 1993-09-11 | 1994-09-12 | Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0725825B1 (es) |
| JP (1) | JPH09502348A (es) |
| CN (1) | CN1135237A (es) |
| AT (1) | ATE199260T1 (es) |
| AU (1) | AU682893B2 (es) |
| BR (1) | BR9407531A (es) |
| CA (1) | CA2171544C (es) |
| CZ (1) | CZ287808B6 (es) |
| DE (1) | DE69426725T2 (es) |
| ES (1) | ES2156902T3 (es) |
| HU (1) | HU219507B (es) |
| PT (1) | PT725825E (es) |
| RU (1) | RU2181379C2 (es) |
| UA (1) | UA43350C2 (es) |
| WO (1) | WO1995007354A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69527089T2 (de) * | 1995-04-19 | 2003-01-02 | Polymun Scientific Immunbiologische Forschung Gmbh, Wien | Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe |
| US6319890B1 (en) | 1996-12-30 | 2001-11-20 | Manfred P. Dierich | Inhibition of binding of complement Factor H |
| CN100383158C (zh) * | 1998-03-23 | 2008-04-23 | 特莱默里斯公司 | 关于肽合成的方法以及组合物 |
| US6482928B1 (en) * | 1999-04-13 | 2002-11-19 | Aventis Pasteur Limited And University Of Toronto | Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5 |
| CN1172717C (zh) * | 2000-08-18 | 2004-10-27 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
| FR2851165A1 (fr) * | 2003-02-19 | 2004-08-20 | Aventis Pasteur | Antigene derivant de l'helice c de la proteine gp41 |
| US20100028415A1 (en) | 2005-04-12 | 2010-02-04 | Haynes Barton F | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus |
| EP1754715A1 (de) | 2005-08-19 | 2007-02-21 | Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut | Impfstoff auf Basis virusneutralisierender Antikörper |
| US8956627B2 (en) | 2007-04-13 | 2015-02-17 | Duke University | Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates |
| EA025275B1 (ru) * | 2009-02-06 | 2016-12-30 | Майметикс Корпорейшн | Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич |
| US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69311764T2 (de) * | 1992-05-14 | 1998-02-05 | Polymun Scient Immunbio Forsch | Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren |
| US5817767A (en) * | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
-
1994
- 1994-09-12 ES ES94927602T patent/ES2156902T3/es not_active Expired - Lifetime
- 1994-09-12 UA UA96030897A patent/UA43350C2/uk unknown
- 1994-09-12 PT PT94927602T patent/PT725825E/pt unknown
- 1994-09-12 WO PCT/EP1994/003039 patent/WO1995007354A1/en active IP Right Grant
- 1994-09-12 AU AU76965/94A patent/AU682893B2/en not_active Ceased
- 1994-09-12 AT AT94927602T patent/ATE199260T1/de not_active IP Right Cessation
- 1994-09-12 RU RU96108781/13A patent/RU2181379C2/ru not_active IP Right Cessation
- 1994-09-12 BR BR9407531A patent/BR9407531A/pt not_active Application Discontinuation
- 1994-09-12 EP EP94927602A patent/EP0725825B1/en not_active Expired - Lifetime
- 1994-09-12 CA CA002171544A patent/CA2171544C/en not_active Expired - Fee Related
- 1994-09-12 HU HU9600587A patent/HU219507B/hu not_active IP Right Cessation
- 1994-09-12 JP JP7508473A patent/JPH09502348A/ja not_active Ceased
- 1994-09-12 CZ CZ1996741A patent/CZ287808B6/cs not_active IP Right Cessation
- 1994-09-12 CN CN94194035A patent/CN1135237A/zh active Pending
- 1994-09-12 DE DE69426725T patent/DE69426725T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT725825E (pt) | 2001-08-30 |
| ATE199260T1 (de) | 2001-03-15 |
| CZ74196A3 (en) | 1996-07-17 |
| CZ287808B6 (en) | 2001-02-14 |
| HUT76102A (en) | 1997-06-30 |
| CN1135237A (zh) | 1996-11-06 |
| JPH09502348A (ja) | 1997-03-11 |
| DE69426725T2 (de) | 2001-09-06 |
| DE69426725D1 (de) | 2001-03-29 |
| CA2171544C (en) | 2003-06-24 |
| HU9600587D0 (en) | 1996-05-28 |
| RU2181379C2 (ru) | 2002-04-20 |
| UA43350C2 (uk) | 2001-12-17 |
| AU682893B2 (en) | 1997-10-23 |
| BR9407531A (pt) | 1997-08-26 |
| EP0725825B1 (en) | 2001-02-21 |
| AU7696594A (en) | 1995-03-27 |
| CA2171544A1 (en) | 1995-03-16 |
| WO1995007354A1 (en) | 1995-03-16 |
| HU219507B (hu) | 2001-04-28 |
| EP0725825A1 (en) | 1996-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6190666B1 (en) | DNA expression systems based on alphaviruses | |
| Binley et al. | Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | |
| ES2053413T3 (es) | Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes. | |
| Hinkula et al. | Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes | |
| DE60037450D1 (de) | Funf-helix protein | |
| ES2156902T3 (es) | Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes. | |
| CY1108638T1 (el) | Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων | |
| NO921969L (no) | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener | |
| EP0339504A3 (en) | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals | |
| CY1110927T1 (el) | Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων | |
| CA2230925A1 (en) | Fusion protein delivery system and uses thereof | |
| US6770283B1 (en) | DNA expression systems based on alphaviruses | |
| AR029810A1 (es) | Metodos y composiciones para la inhibicion de los acontecimientos asociados con la fusion de membrana, incluyendo la transmision de rsv | |
| DE69231705D1 (de) | Gag-Env Fusion-Antigen aus HIV | |
| DE3854550D1 (de) | HIV-Peptide und Methoden für den Nachweis von HIV. | |
| ATE177843T1 (de) | Peptomere mit erhöhter immunogenizität | |
| RU96108781A (ru) | Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1 | |
| KLANIECKI et al. | Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus | |
| ES2074591T3 (es) | Expresion de polipeptidos de vih 1 y 2 y su utilizacion. | |
| DK0541753T3 (da) | Hidtil ukendt hybrid, opløselig og ikke-spaltelig gp160-variant | |
| ES2137378T3 (es) | Estructuras peptidicas poliramificadas para ser utilizadas contra el hiv. | |
| ES2079493T3 (es) | Proteina de membrana externa p1 y peptidos haemophilus influenzae tipo b. | |
| ES2095899T3 (es) | Peptidos de la proteina gag de vih, su preparacion y uso. | |
| ES2071038T3 (es) | Peptidos asociados al hiv. | |
| RU2000106709A (ru) | Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 725825 Country of ref document: ES |